Taysha Gene Therapies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Taysha Gene Therapies has a total shareholder equity of $108.9M and total debt of $37.8M, which brings its debt-to-equity ratio to 34.8%. Its total assets and total liabilities are $200.4M and $91.5M respectively.

Anahtar bilgiler

34.8%

Borç/özkaynak oranı

US$37.84m

Borç

Faiz karşılama oranı	n/a
Nakit	US$172.74m
Eşitlik	US$108.87m
Toplam yükümlülükler	US$91.53m
Toplam varlıklar	US$200.39m

Son finansal sağlık güncellemeleri

Recent updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Oct 14

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Jun 27

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Jun 20

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Apr 20

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: TSHA's short term assets ($178.5M) exceed its short term liabilities ($34.2M).

Uzun Vadeli Yükümlülükler: TSHA's short term assets ($178.5M) exceed its long term liabilities ($57.3M).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: TSHA has more cash than its total debt.

Borcun Azaltılması: Insufficient data to determine if TSHA's debt to equity ratio has reduced over the past 5 years.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: TSHA has sufficient cash runway for more than a year based on its current free cash flow.

Tahmini Nakit Akışı: TSHA has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 7.1% each year.

Taysha Gene Therapies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Taysha Gene Therapies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities

Recent updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Consensus revenue estimates decrease by 25%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Taysha Gene Therapies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $74.981029 million.

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Taysha Gene Therapies, Inc. Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Taysha Gene Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Taysha Gene Therapies, Inc., Annual General Meeting, May 29, 2024

Consensus revenue estimates increase by 23%

Consensus revenue estimates increase by 25%

Price target increased by 7.9% to US$6.06

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Taysha Gene Therapies, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Taysha: Produces Solid Data But Has Abandoned Programs

Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Board Observer recently bought US$163k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Taysha Gene Therapies, Inc. Announces Second Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

CFO & Corporate Secretary notifies of intention to sell stock

Taysha Gene Therapies, Inc. Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Consensus estimates of losses per share improve by 33%

Taysha Gene Therapies, Inc. announced that it expects to receive $149.952767 million in funding from a group of investors

Taysha Gene Therapies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities

Taysha Gene Therapies, Inc. Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Insider recently sold US$61k worth of stock

New minor risk - Insider selling

Insider recently sold US$308k worth of stock

Taysha Gene Therapies, Inc. Announces First Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc., Annual General Meeting, Jun 22, 2023

Taysha Gene Therapies, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 20% to US$5.77

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy

Price target decreased by 11% to US$14.57

Taysha Gene Therapies, Inc. Announces Separation Suyash Prasad as Chief Medical Officer

Price target decreased to US$15.36

Price target decreased to US$16.79

High number of new and inexperienced directors

Price target decreased to US$17.21

Taysha Gene Therapies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Price target decreased to US$22.46

Taysha Gene Therapies, Inc. announced that it expects to receive $50 million in funding from Astellas Pharma Inc.

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 2000 Growth Index

Chief Technical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome

Price target decreased to US$39.07

Taysha Gene Therapies Gets A 'Thumbs Up'

Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease At 18th Annual WORLDSymposium

Independent Director recently bought US$80k worth of stock

Taysha Gene Therapies, Inc. Reports Positive Clinical Efficacy and Safety Data for the High Dose Cohort of 3.5X10 Total Vg

Taysha Gene Therapies, Inc. Announces Positive Initial Biomarker Data for TSHA-101

High number of new and inexperienced directors

Finansal Durum Analizi